Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

免疫原性 肺炎球菌结合疫苗 医学 耐受性 肺炎球菌疫苗 人口 不利影响 结合疫苗 血清型 免疫学 抗原 内科学 儿科 肺炎链球菌 生物 微生物学 抗生素 环境卫生
作者
James Wassil,Maggie Sisti,Jeff Fairman,Matthew Davis,Carlos Fierro,Sean Bennett,Derek R. Johnson,Thi‐Sau Migone,Kien T. Nguyen,Paul Sauer,Michelle Currie,Sam Iki,Jakub K. Simon
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (3): 308-318 被引量:10
标识
DOI:10.1016/s1473-3099(23)00572-8
摘要

Summary

Background

Despite substantial reductions in pneumococcal disease with the availability of pneumococcal conjugate vaccines, a significant burden of pneumococcal disease remains due to the diversity of serotypes combined with serotype replacement. We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197 (eCRM) as the carrier protein, increasing serotype coverage while minimising carrier suppression. The aim of this clinical trial was to assess the safety, tolerability, and immunogenicity of three different doses of VAX-24 compared to pneumococcal 20-valent conjugate vaccine (PCV20).

Methods

This was a phase 1/2, randomised, double-masked study of VAX-24 versus PCV20 conducted in the USA. Key inclusion criteria included being a male or female aged 18 to 64 years in good health; key exclusion criteria included previous history of pneumococcal disease, receipt of a licensed or investigational pneumococcal vaccine, or immunosuppressive therapy. Participants were randomly allocated in a 1:1:1:1 ratio by permuted block to receive one dose of VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens), or PCV20. The safety population included all participants with safety data. The immunogenicity population was as per-treatment in phase 2. Primary outcome measures included solicited and unsolicited adverse events. Secondary outcomes included serotype-specific opsonophagocytic activity (OPA) geometric mean titres (GMT), and IgG geometric mean concentrations (GMC) were measured 1 month postvaccination. Traditional non-inferiority criteria included OPA geometric mean ratio (GMR), with a lower bound of the two sided 95% CI of greater than 0·5 for shared serotypes. This completed trial is registered at ClinicalTrials.gov, NCT05266456.

Findings

Safety profiles were comparable among the treatment groups, with 170 of 209 participants (81%, 95% CI 75·2–86·2) to 178 of 207 participants (86%, 80·5–90·4) reporting at least one solicited adverse event among the three VAX-24 groups. 24 of 207 participants (12%, 7·6–16·8) to 32 of 209 of participants (15%, 10·7–20·9) experiened an unsolicited treatment emergent adverse event within 1 month postvaccination. VAX-24 2·2 μg met traditional OPA GMR non-inferiority criteria for all 20 shared serotypes; 16 serotypes elicited GMR point estimates greater than 1·0, and four reached the lower bound of the two-sided 95% CI greater than 1·0.

Interpretation

VAX-24 had a safety profile similar to PCV20 at all doses, with the 2·2 μg dose showing increased serotype coverage with decreased carrier suppression.

Funding

Vaxcyte.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ECHO完成签到,获得积分10
刚刚
Lucas应助Fang Xianxin采纳,获得10
1秒前
xiaoyao完成签到,获得积分10
2秒前
asss完成签到,获得积分10
2秒前
Y123发布了新的文献求助30
3秒前
LOVER完成签到 ,获得积分10
4秒前
松松完成签到 ,获得积分10
4秒前
6秒前
nater4ver完成签到,获得积分10
7秒前
UU发布了新的文献求助10
9秒前
超帅鸭子完成签到,获得积分10
9秒前
LXZ完成签到,获得积分10
9秒前
依惜完成签到,获得积分10
9秒前
zhaokunfeng关注了科研通微信公众号
9秒前
赫青亦完成签到 ,获得积分10
9秒前
exy完成签到,获得积分10
10秒前
zhaohu47完成签到,获得积分10
11秒前
超帅鸭子发布了新的文献求助10
11秒前
每每反完成签到,获得积分10
13秒前
凡凡完成签到 ,获得积分10
14秒前
15秒前
呆鹅喵喵完成签到,获得积分10
15秒前
忧心的洙完成签到,获得积分10
16秒前
123完成签到,获得积分10
16秒前
青青草完成签到,获得积分10
18秒前
Fang Xianxin完成签到,获得积分20
18秒前
yue发布了新的文献求助10
18秒前
小甘看世界完成签到,获得积分0
20秒前
量子星尘发布了新的文献求助10
20秒前
张今天也要做科研呀完成签到,获得积分10
21秒前
nater3ver完成签到,获得积分10
22秒前
22秒前
自然怀梦完成签到,获得积分10
22秒前
轻歌水越完成签到 ,获得积分10
22秒前
执意完成签到 ,获得积分10
23秒前
大模型应助Coral采纳,获得10
23秒前
songyl完成签到,获得积分10
24秒前
怡然问晴发布了新的文献求助20
25秒前
24K纯帅完成签到,获得积分0
25秒前
LL发布了新的文献求助20
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029